Yunnan Creates One Of China's Largest Biopharma Pilot Production Centers
This article was originally published in PharmAsia News
Executive SummaryThe Yunnan Institute of Materia Medica has established a series of R&D platforms, notably China's largest biopharma pilot production center
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.